Esophageal carcinoma

Last revised by Michael Francois Nel on 19 Sep 2023

Esophageal carcinoma is relatively uncommon. It tends to present with increasing dysphagia, initially to solids and progressing to liquids as the tumor increases in size, obstructing the lumen of the esophagus.

Esophageal cancer is responsible for <1% of all cancers and 4-10% of all gastrointestinal malignancies. There is recognized male preponderance with the squamous cell subtype, M:F 4:1. 

The incidence of the subtypes has regional variation. The squamous cell subtype has the greatest worldwide incidence (~90%), but the adenocarcinoma subtype is more common in many parts of North America and Europe. In addition, there are certain regions where individuals are at particularly high risk of developing esophageal cancer, e.g. Iran, Malawi, Zimbabwe, Mongolia, Italy, and China.

Predisposing factors include 8:

Patients present with progressive dysphagiaweight loss, chronic worsening gastro-esophageal reflux and hoarseness, cough, vocal cord paralysis, or other signs and symptoms of mediastinal invasion.

* in the western world adenocarcinoma is as common or even slightly more common than squamous cell carcinoma

  • polypoid/fungating (most common)

    • sessile/pedunculated tumor

    • lobulated surface protruding

    • irregular, polycyclic, overhanging, step-like "apple core" lesion

  • ulcerating: large ulcer niche within a bulging mass

  • infiltrating: gradual narrowing with a smooth transition

  • superficial spreading carcinoma

See the separate articles by histology:

  • lymphatic

    • anterior jugular chain and supraclavicular nodes (primary in upper 1/3)

    • para-esophageal and subdiaphragmatic nodes (primary in middle 1/3)

    • mediastinal and paracardiac and celiac trunk nodes (primary in lower 1/3)

  • hematogenous: lung, liver, adrenal glands

A combination of CT scan, transesophageal ultrasound, and PET-CT are used for staging of the disease. CT is the best initial modality for detection of the distant metastasis, gross direct invasion, and enlarged lymph nodes. Ultrasound is the most sensitive modality for assessment of the depth of invasion and regional enlarged lymph nodes. PET can be useful for restaging after the initial neoadjuvant therapy 7

Many indirect signs can be sought on a chest radiograph and these include:

  • irregular stricture

  • prestricture dilatation with 'hold up'

  • shouldering of the stricture

The most accurate imaging modality for the T staging of esophageal cancer. It defines the layers of the esophageal wall hence can differentiate T1, T2, and T3 tumors.

The esophagus consists of five layers:

  1. first hyperechoic layer represents the interface between the balloon and the superficial mucosa

  2. second hypoechoic layer represents the lamina propria and muscularis mucosae

  3. third hyperechoic layer represents the submucosa

  4. fourth hypoechoic layer represents the muscularis propria

  5. fifth layer represents the interface between the adventitia and surrounding tissues

  • eccentric or circumferential wall thickening >5 mm

  • periesophageal soft tissue and fat stranding

  • dilated fluid- and debris-filled esophageal lumen is proximal to an obstructing lesion

  • tracheobronchial invasion appears as a displacement of the airway (usually the trachea or left mainstem bronchus) as a result of mass effect by the esophageal tumor

  • aortic invasion

FDG PET-CT is useful for detecting esophageal primary tumors yet it has little role in helping determine the specific T classification because it provides limited information about the depth of tumor invasion.

PET-CT is also superior to CT for detecting lymph node metastases and can depict metastases in normal-sized lymph nodes through the uptake of FDG. 

PET-CT has a primary role in the depiction of distant sites of metastatic disease.

The most common sites of distant metastases detected at PET (but frequently missed at CT) are the bones and liver. 

The 5-year mortality depends on the stage of the tumor. Unfortunately, most cases present with regional or distant metastatic disease (30% and 40% respectively).

  • localized disease: ~40% 5-year survival

  • distant metastatic disease: ~5% 5-year survival

Endoscopic mucosal resection, without or with localized ablation is an option for localized (T1a) disease. These epithelial tumors are usually <2 cm, asymptomatic, and noncircumferential.

For T1b tumors and above, surgical options are mostly limited to esophagectomy (including sometimes with palliative colonic interposition (see case 19)).

  • fistula formation to the trachea (5-10%), bronchi or mediastinum: can be either due to direct tumor progression or iatrogenic effects (e.g. radiation therapy) 

  • esophageal perforation

Imaging differential considerations include:

ADVERTISEMENT: Supporters see fewer/no ads

Cases and figures

  • Figure 1: endoscopic view
    Drag here to reorder.
  • Case 1: squamous cell carcinoma barium swallow
    Drag here to reorder.
  • Case 2 : transesophageal endoscopic ultrasound
    Drag here to reorder.
  • Case 3: CT
    Drag here to reorder.
  • Case 4: Barium swallow
    Drag here to reorder.
  • Case 5: esophageal cancer and peptic stricture
    Drag here to reorder.
  • Case 6
    Drag here to reorder.
  • Case 7: adenocarcinoma
    Drag here to reorder.
  • Case 8
    Drag here to reorder.
  • Case 9: squamous cell cancer with lung metastases
    Drag here to reorder.
  • Case 10: with recurrent laryngeal nerve palsy
    Drag here to reorder.
  • Case 11: mid esophagus
    Drag here to reorder.
  • Case 12
    Drag here to reorder.
  • Case 13
    Drag here to reorder.
  • Case 14
    Drag here to reorder.
  • Case 15: fluoroscopy
    Drag here to reorder.
  • Case 16
    Drag here to reorder.
  • Case 17: squamous cell carcinoma
    Drag here to reorder.
  • Case 18: with esophageal stent
    Drag here to reorder.
  • Case 19: treated esophageal cancer by colonic interposition
    Drag here to reorder.
  • Case 20: with a aorto-esophageal fistula
    Drag here to reorder.
  • Case 21: incidental on PET-CT
    Drag here to reorder.
  • Case 22
    Drag here to reorder.
  • Case 23
    Drag here to reorder.
  • Case 24: mid esophageal squamous cell carcinoma
    Drag here to reorder.
  • Case 25
    Drag here to reorder.
  • Case 26
    Drag here to reorder.
  • Case 27
    Drag here to reorder.
  • Case 28
    Drag here to reorder.
  • Case 29
    Drag here to reorder.
  • Case 30
    Drag here to reorder.
  • Case 31
    Drag here to reorder.
  • Case 32: metastatic esophagogastric cancer
    Drag here to reorder.
  • Case 33
    Drag here to reorder.
  • Case 34
    Drag here to reorder.
  • Case 35: metastatic
    Drag here to reorder.
  • Case 36
    Drag here to reorder.
  • Case 37: with migrated stent
    Drag here to reorder.
  • Case 38
    Drag here to reorder.
  • Case 39
    Drag here to reorder.
  • Case 40
    Drag here to reorder.
  • Case 41
    Drag here to reorder.
  • Case 42: PET CT
    Drag here to reorder.